Paediatric Consumer Health in Spain

PROSPECTS

Spanish healthcare system to limit growth

Paediatric consumer health recorded a similar performance in 2018 to the previous year. Performance is strongly influenced by the Spanish healthcare system, which allows the same active ingredient in both reimbursable and non-reimbursable products, which reduces the potential of paediatric consumer health.

Shrinking consumer base

In 2018, Spain recorded the lowest birth rate in 40 years. No major rise in the birth rate is expected unless Spanish authorities take a more active role in promoting an increase.

The same categories support growth

In 2018, cough, cold and allergy remedies and also analgesics were the two categories supporting growth of paediatric consumer health. As with adult products, the higher level of prevalence of the flu for a longer period supported sales of both categories.

New ailments to support sales

As is happening in other developed countries, children in Spain are set to suffer from new aliments due to their somewhat unhealthy lifestyles. Spanish children spend too many hours playing with technology devices and take part in little sport or playing outside.

COMPETITIVE LANDSCAPE

In the hands of a few

As earlier in the review period, paediatric consumer health continued to be led in 2018 by the brand Dalsy. This paediatric ibuprofen accounted for over a fifth of category value sales; however, its value share declined in 2018 and this was linked to a shortage of supply, which was so important that explanations were given by Mylan on the national news.

OTC dermatological sales are strong

Mylan was followed by Johnson & Johnson in second and Reckitt Benckiser España in third in 2018. These two companies’ strengths lie within dermatological products.

Files are delivered directly into your account within a few minutes of purchase.